Anika Therapeutics Inc. (ANIK)

53.12
0.61 1.14
NASDAQ : Health Technology
Prev Close 53.73
Open 53.90
Day Low/High 53.03 / 54.61
52 Wk Low/High 29.01 / 58.93
Volume 419.30K
Avg Volume 190.70K
Exchange NASDAQ
Shares Outstanding 13.78M
Market Cap 748.69M
EPS 1.30
P/E Ratio 26.98
Div & Yield N.A. (N.A)

Latest News

Anika To Participate In The 2019 Morgan Stanley Global Healthcare Conference On September 10, 2019

Anika To Participate In The 2019 Morgan Stanley Global Healthcare Conference On September 10, 2019

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that Joseph Darling, President and Chief...

Anika Announces Successful Completion Of First Human Surgical Procedure With Injectable HA-Based Bone Repair Therapy

Anika Announces Successful Completion Of First Human Surgical Procedure With Injectable HA-Based Bone Repair Therapy

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the successful completion of the first...

Anika Therapeutics Gets a Quant Upgrade to Buy, Adding to Its Technical Breakout

Anika Therapeutics Gets a Quant Upgrade to Buy, Adding to Its Technical Breakout

Let's check out the latest charts and indicators.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANIK, AXTA, EIX, FDC, HOMB, NVCR, PSEC Downgrades: F, MAS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

ANIK Crosses Above Average Analyst Target

ANIK Crosses Above Average Analyst Target

In recent trading, shares of Anika Therapeutics Inc. have crossed above the average analyst 12-month target price of $42.00, changing hands for $52.60/share.

Anika Reports Second Quarter 2019 Financial Results

Anika Reports Second Quarter 2019 Financial Results

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the second quarter...

Noteworthy Monday Option Activity: ANIK, SIG, ISRG

Noteworthy Monday Option Activity: ANIK, SIG, ISRG

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Anika Therapeutics Inc. , where a total volume of 1,571 contracts has been traded thus far today, a contract volume which is representative of approximately 157,100 underlying shares (given that every 1 contract represents 100 underlying shares).

Anika To Exhibit Its HA-Based Bone Repair Therapy At The 2019 American Orthopaedic Society For Sports Medicine Annual Meeting

Anika To Exhibit Its HA-Based Bone Repair Therapy At The 2019 American Orthopaedic Society For Sports Medicine Annual Meeting

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to exhibit its injectable,...

Anika To Issue Second-Quarter 2019 Financial Results And Business Highlights On Wednesday, July 24

Anika To Issue Second-Quarter 2019 Financial Results And Business Highlights On Wednesday, July 24

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2019 financial results after the close of the market on Wednesday, July 24, 2019 and hold its investor conference call on the same day, Wednesday,...

Anika Appoints James Loerop As Executive Vice President Of Business Development And Strategic Planning

Anika Appoints James Loerop As Executive Vice President Of Business Development And Strategic Planning

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of James Loerop to the...

Anika Announces Plans To Showcase HYALOFAST Hyaluronic Acid-Based Cartilage Repair Scaffold At The 2019 International Cartilage Regeneration And Joint Preservation Society (ICRS) Focus Meeting

Anika Announces Plans To Showcase HYALOFAST Hyaluronic Acid-Based Cartilage Repair Scaffold At The 2019 International Cartilage Regeneration And Joint Preservation Society (ICRS) Focus Meeting

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to showcase HYALOFAST, a...

Anika To Showcase Regenerative Medicine And Orthobiologics Portfolio At The 12th Biennial International Society Of Arthroscopy, Knee Surgery And Orthopaedic Sports Medicine Congress

Anika To Showcase Regenerative Medicine And Orthobiologics Portfolio At The 12th Biennial International Society Of Arthroscopy, Knee Surgery And Orthopaedic Sports Medicine Congress

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to showcase its regenerative...

Notable Monday Option Activity: ANIK, PETS, DOVA

Notable Monday Option Activity: ANIK, PETS, DOVA

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Anika Therapeutics Inc. , where a total volume of 1,471 contracts has been traded thus far today, a contract volume which is representative of approximately 147,100 underlying shares (given that every 1 contract represents 100 underlying shares).

Anika To Participate In Two Investor Events In May 2019

Anika To Participate In Two Investor Events In May 2019

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that the Company will participate in the...

Anika Therapeutics (ANIK) Shares Cross Above 200 DMA

Anika Therapeutics (ANIK) Shares Cross Above 200 DMA

In trading on Friday, shares of Anika Therapeutics Inc. crossed above their 200 day moving average of $36.21, changing hands as high as $38.76 per share.

Anika Reports First Quarter 2019 Financial Results

Anika Reports First Quarter 2019 Financial Results

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today reported financial results for the first quarter...

Anika Announces $50 Million Share Repurchase Program

Anika Announces $50 Million Share Repurchase Program

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its Board of Directors has authorized...

Anika Appoints Stephen Goldy As Vice President Of U.S. Sales

Anika Appoints Stephen Goldy As Vice President Of U.S. Sales

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of Stephen Goldy to the...

Anika To Issue First-Quarter 2019 Financial Results And Business Highlights On Thursday, May 2

Anika To Issue First-Quarter 2019 Financial Results And Business Highlights On Thursday, May 2

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2019 financial results after the close of the market on Thursday, May 2, 2019 and hold its investor conference call on the same day, Thursday, May 2,...

Anika To Highlight Regenerative Medicine And Orthobiologics Portfolio At 2019 Asia Pacific Orthopaedic Association Sports Meeting

Anika To Highlight Regenerative Medicine And Orthobiologics Portfolio At 2019 Asia Pacific Orthopaedic Association Sports Meeting

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to showcase its regenerative...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: FGEN, GOLF, HNGR, MO, NOMD, NRE, PYX Downgrades: ANIK, BDC, CRHM, ETM, RUN, SEAS, TKC, WBA, XXII Initiations: ADT, EYE Read on to get TheStreet Quant Ratings' detailed report:

Anika Appoints Robert Richard, Ph.D. As Vice President Of Research And Development

Anika Appoints Robert Richard, Ph.D. As Vice President Of Research And Development

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of Robert Richard, Ph.

Anika To Showcase Commercial And Pipeline Portfolio At 2019 AAOS Annual Meeting

Anika To Showcase Commercial And Pipeline Portfolio At 2019 AAOS Annual Meeting

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to showcase its innovative...

Noteworthy Tuesday Option Activity: ANIK, QCOM, OSPN

Noteworthy Tuesday Option Activity: ANIK, QCOM, OSPN

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Anika Therapeutics Inc. , where a total volume of 2,361 contracts has been traded thus far today, a contract volume which is representative of approximately 236,100 underlying shares (given that every 1 contract represents 100 underlying shares).

Relative Strength Alert For Anika Therapeutics

Relative Strength Alert For Anika Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANIK, EHTH, ENV, FUSB, IBP, NBEV, OXSQ, PK, SWM, THRM, XRX Downgrades: BRK.A, CENTA, EVH, KNSL, PAAS, PLAB, RTRX, TGP Initiations: CASA Read on to get TheStreet Quant Ratings' detailed report:

ANIK Makes Notable Cross Below Critical Moving Average

ANIK Makes Notable Cross Below Critical Moving Average

In trading on Friday, shares of Anika Therapeutics Inc. crossed below their 200 day moving average of $37.80, changing hands as low as $32.52 per share.

Anika Reports Fourth Quarter And Full Year 2018 Financial Results

Anika Reports Fourth Quarter And Full Year 2018 Financial Results

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the fourth quarter...

TheStreet Quant Rating: B- (Buy)